<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707081</url>
  </required_header>
  <id_info>
    <org_study_id>Benha 121</org_study_id>
    <nct_id>NCT02707081</nct_id>
  </id_info>
  <brief_title>Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief</brief_title>
  <official_title>Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <brief_summary>
    <textblock>
      Objective: To evaluate intraperitoneal (IP) lidocaine administration and intravenous (IV)
      lidocaine infusion for postoperative pain control after cesarean section.

      Study design: prospective randomized, double-blind, placebo-controlled study. Patients and
      methods: Initially, 165 pregnant full-term females, indicated to be underwent elective
      cesarean delivery for various indications were randomized equally to either group C (control,
      IP and IV saline), group IP (intraperitoneal lidocaine administration), or group IV
      (intravenous lidocaine infusion).Five patients were excluded from each group for various
      reasons. The outcome measures were postoperative pain scoring, total pethidine consumption
      and the need for postoperative analgesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain scoring (number)</measure>
    <time_frame>First 24 hours postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The need for rescue postoperative analgesia.</measure>
    <time_frame>First 24 hours postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pethidine consumption in 24 hours (mg)</measure>
    <time_frame>First 24 hours postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to bowel sounds, hours</measure>
    <time_frame>First 3 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to start regular diet, days</measure>
    <time_frame>First 3 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay , days</measure>
    <time_frame>First 3 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any reported side effects</measure>
    <time_frame>First 3 days postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postcesarean Pain Relief</condition>
  <arm_group>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline was given both intraperitoneally and intravenously during caesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraperitoneal instillation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous injection group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous normal saline</intervention_name>
    <description>Normal saline in a volume equivalent to that used in intravenous lidocaine group</description>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_label>Intraperitoneal instillation group</arm_group_label>
    <other_name>IV Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraperitoneal normal saline</intervention_name>
    <description>Patients received 00 ml of saline intraperitoneally</description>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_label>Intravenous injection group</arm_group_label>
    <other_name>IP Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraperitoneal Lidocaine</intervention_name>
    <description>Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.</description>
    <arm_group_label>Intraperitoneal instillation group</arm_group_label>
    <other_name>IP Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Lidocaine</intervention_name>
    <description>Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.</description>
    <arm_group_label>Intravenous injection group</arm_group_label>
    <other_name>IV Lidocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy, more than or equal completed 37 gestational weeks, indicated to
             undergo elective cesarean delivery for various indications

        Exclusion Criteria:

          -  extreme of age (below 18 or above 40 year), uncooperative patients, women under spinal
             anesthesia, previous abdominal scars, including previous cesarean or myomectomy,
             multiple gestation, BMI &gt;35 kg/mÂ², chorioamnionitis, hypersensitivity or
             contraindications to lidocaine, bronchial asthma, bleeding diathesis, pregnancy
             induced-hypertension, liver or kidney diseases, diabetes mellitus, and patients with
             psychological disturbance, or any form of chronic pain before or during pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Ahmed Walid Anwar Murad</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

